Yesterday, the General Counsel of Arrowhead Research (ARWR), Patrick O. O’Brien, sold shares of ARWR for $746.4K.
In addition to Patrick O. O’Brien, one other ARWR executive reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Arrowhead Research’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $48.15 million and quarterly net profit of $23.9 million. In comparison, last year the company earned revenue of $650.1K and had a GAAP net loss of $14.88 million. ARWR’s market cap is $2.37B and the company has a P/E ratio of 367.50. Currently, Arrowhead Research has an average volume of 2.03M.
Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $28.38, reflecting a 13.6% upside.
In the last 30 days, insiders have sold $746.4K worth of ARWR shares and purchased $105.1K worth of ARWR shares. The insider sentiment on Arrowhead Research has been negative according to 41 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
